Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia

4 Feb 2022

Abstract excerpt

We report the emergence of imipenem-relebactam nonsusceptible Pseudomonas aeruginosa in 5 patients treated for nosocomial pneumonia for 10-28 days. Genome sequence analysis identified treatment-emergent mutations in MexAB-OprM and/or MexEF-OprN efflux operons that arose independently in each patient across distinct P. aeruginosa sequence types. Testing with efflux-inhibitor PAβN restored imipenem-relebactam...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotics Pharmacokinetics and Efficacy
Share to Pneumonia and Respiratory Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35136967
DOI: 10.1093/cid/ciac097

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa PneumoniaPMID 35136967Read ↗

First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa.Semantic proximity Read ↗

Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.Semantic proximity Read ↗

Acquisition of antimicrobial-resistant variants in repeated infections caused by Pseudomonas aeruginosa revealed by whole genome sequencing.Semantic proximity Read ↗

Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016.Semantic proximity Read ↗

Emergence of Resistance to Novel Cephalosporin–β-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux PumpSemantic proximity Read ↗

Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosaSemantic proximity Read ↗

Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infectionsSemantic proximity Read ↗

Emerging resistance mechanisms to newer β-lactams in Pseudomonas aeruginosa.Semantic proximity Read ↗

Ceftazidime-avibactam resistance evolution in Pseudomonas aeruginosa and implications for cross-resistance to other novel β-lactams.Semantic proximity Read ↗

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosaSemantic proximity Read ↗

In vitro exposure to non-antipseudomonal antibiotics (NAPA) induces Pseudomonas aeruginosa resistance to antipseudomonal antibiotics (APA).Semantic proximity Read ↗

Development and Persistence of Antimicrobial Resistance in Pseudomonas aeruginosa : a Longitudinal Observation in Mechanically Ventilated PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.